OxyContin has always been the world's top-selling opioid painkiller and generated billions in sales for privately-held Purdue.
In a statement to The Verge, a Purdue spokesperson says that "we have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers".
Opioids killed more than 42,000 people in 2016 according to the Centers for Disease Control and Prevention, and 40 percent of those deaths involved a prescription opioid. The company has been unable to develop or buy a drug to replace OxyContin's sales.
Among other opioid producers, Endo International Plc agreed in July to pull its Opana ER painkiller after the Food and Drug Administration called for its withdrawal.
A drugmaker says it will no longer market its opioid products in doctors' offices after facing backlash for the way the industry promotes the addictive drugs.
The boom in OxyContin prescriptions, and the resulting expansion of the deadly abuse of opioids, has been consistently blamed on Purdue's aggressive and misleading marketing of the drug.
At least 14 states have sued Purdue, and many cities including Greenfield and Springfield in Western Massachusetts.
Winter Olympics Organisers Apologise to Iran over Samsung Gift Gaffe
Iran also called for an apology from Samsung , claiming that its trade relations would otherwise be "greatly affected". The cases will feature the logo of the Paralympic Games.
Eventually, Purdue acknowledged that its promotions exaggerated the drug's safety and minimized the risks of addiction.
"The decision by a manufacturer to stop pushing opioid pain medications is late, but better late than never", Cidambi told USA TODAY.
Purdue's sales representatives will now focus on the Symproic drug created to treat opioid-induced constipation, and other non-opioid products.
Purdue has denied the allegations in the various lawsuits.
The company in 2007 paid out $600 million to settle civil and criminal charges related to the drug's marketing, with three company executives agreeing to pay an additional $34.5 million.
U.S. President Donald Trump has drawn criticism for his response to the opioid crisis.